Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K N Price

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study GroupB A Gusterson, R D Gelber, A Goldhirsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study GroupA M Neville, R Bettelheim, R D Gelber, et al.
British Journal of Cancer|April 26, 2012
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancerK Ribi, J Aldridge, K-A Phillips, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2011
Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trialB Ejlertsen, J Aldridge, K V Nielsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2009
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-upM Colleoni, Z Sun, G Martinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2008
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancerA Ravaioli, F Monti, M M Regan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?M M Regan, O Pagani, B Walley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2015
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trialE Munzone, A Giobbie-Hurder, B A Gusterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2012
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group reportP Karlsson, B F Cole, B H Chua, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2006
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)B C Pestalozzi, D Zahrieh, K N Price, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study GroupB A Gusterson, R D Gelber, A Goldhirsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study GroupA M Neville, R Bettelheim, R D Gelber, et al.
British Journal of Cancer|April 26, 2012
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancerK Ribi, J Aldridge, K-A Phillips, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2011
Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trialB Ejlertsen, J Aldridge, K V Nielsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2009
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-upM Colleoni, Z Sun, G Martinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2008
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancerA Ravaioli, F Monti, M M Regan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?M M Regan, O Pagani, B Walley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2015
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trialE Munzone, A Giobbie-Hurder, B A Gusterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2012
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group reportP Karlsson, B F Cole, B H Chua, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2006
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)B C Pestalozzi, D Zahrieh, K N Price, et al.
Pageof 4